Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Price Target of $47.40

Key Points

• Analysts have a “Moderate Buy” consensus on Tyra Biosciences: 11 of 15 rate it Buy, two Strong Buy, one Hold, and one Sell. The average one-year price target is $47.40.
• Tyra reported a quarterly loss of $0.74 per share, missing the $0.67 loss analysts expected; reports also said its third-quarter net loss widened.
• Shares opened at $20.02, below their 50-day moving average of $21.75 and 200-day average of $29.38. Institutional investors own 84.14% of the stock.

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the fifteen ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $47.40.

A number of equities analysts have weighed in on TYRA shares. Weiss Ratings restated a "sell (d-)" rating on shares of Tyra Biosciences in a research note on Thursday, October 15th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $50.00 price target on shares of Tyra Biosciences in a report on Tuesday, October 6th. Oppenheimer reiterated an "outperform" rating and set a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday, September 22nd. William Blair raised Tyra Biosciences to a "strong-buy" rating in a report on Wednesday, September 23rd. Finally, HC Wainwright decreased their price objective on shares of Tyra Biosciences from $29.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday.

Hedge Funds Weigh In On Tyra Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC raised its position in shares of Tyra Biosciences by 843.4% during the 3rd quarter. Sterling Capital Management LLC now owns 1,217 shares of the company's stock valued at $27,000 after buying an additional 1,088 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Tyra Biosciences during the 3rd quarter worth $67,000. State of Wyoming bought a new stake in shares of Tyra Biosciences during the 2nd quarter worth $76,000. Canada Pension Plan Investment Board purchased a new position in Tyra Biosciences in the second quarter worth $230,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Tyra Biosciences in the second quarter worth $237,000. Hedge funds and other institutional investors own 84.14% of the company's stock.

Recent Tyra Biosciences Headlines

Investors following TYRA have been watching these headlines:

• Positive Sentiment: HC Wainwright kept its Buy rating and $27 price target, while a separate report described analysts as bullish on TYRA. The target suggests potential upside from the recently cited $20.02 price, though it is not a guarantee. Analysts Are Bullish on Top Healthcare Stocks: Claritev (CTEV), Tyra Bioscience (TYRA)
• Negative Sentiment: Tyra’s Q3 loss widened, and it missed the earnings-per-share consensus. Reports also noted shares fell below their 50-day moving average after the disappointing results, reinforcing near-term concerns. Tyra Biosciences' Q3 Net Loss Widens Stock Breaks Below Fifty Day Moving Average on Disappointing Earnings
• Negative Sentiment: HC Wainwright lowered most of its 2027 quarterly and full-year EPS forecasts, including FY2027 to a loss of $2.44 per share from $2.27. Its FY2026 loss estimate also edged lower to $2.64 from $2.60, although the Q4 2026 forecast improved. These revisions signal expectations for greater near-term losses despite the continued Buy rating. HC Wainwright Estimate Changes

Tyra Biosciences Price Performance

TYRA opened at $20.02 on Friday. The company has a fifty day moving average price of $21.75 and a 200-day moving average price of $29.38. The firm has a market capitalization of $1.38 billion, a P/E ratio of -7.58 and a beta of 0.65. Tyra Biosciences has a one year low of $14.84 and a one year high of $40.65.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.07). On average, analysts expect that Tyra Biosciences will post -2.77 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company's pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.